Dexcom is facing scrutiny and class-action lawsuits over alleged safety and accuracy issues with its G7 monitor.

DXCM's Q3 results are likely to benefit from rising G7 use, early Stelo traction and expanding access across Type 2 diabetes ...

T hree people with diabetes died following use of Dexcom’s G7 continuous glucose monitor, according to Hunterbrook Media, ...

The use of CGM has been growing among people without diabetes, including those with prediabetes, particularly with the ...

The parent of a child who wore the device to manage diabetes described failed alerts and inaccurate readings in a complaint.

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired DexCom, Inc. ("DexCom" or the "Company") (NASDAQ:DXCM) securities during ...

Dexcom (($DXCM)) announced an update on their ongoing clinical study. Study Overview: The COMPASS Program, officially titled ‘Continuous ...

Continuous glucose monitors — the tiny sensors once reserved for people with diabetes — are now appearing on the arms of ...

ViCentra announced today that it appointed former Dexcom and Medtronic Diabetes leaders to new executive roles.

A multinational analysis and Swedish registry data show higher dementia mortality after age 80 and a twofold dementia risk in ...

Analysts have set 12-month price targets for DexCom, revealing an average target of $97.15, a high estimate of $106.00, and a ...